PAGln, an Atrial Fibrillation-Linked Gut Microbial Metabolite, Acts as a Promoter of Atrial Myocyte Injury.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, 2011-

Atrial Fibrillation* ; Gastrointestinal Microbiome*; Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism ; Humans ; Myocytes, Cardiac/metabolism ; Ryanodine Receptor Calcium Release Channel/metabolism

Phenylacetylglutamine (PAGln), a gut microbiota (GM)-derived metabolite, is associated with cardiovascular disease. Studies have shown that disordered GM participated in the progression of atrial fibrillation (AF), but the relationship between PAGln and AF is unclear. This study investigated the characteristics of PAGln in AF patients and its impact on atrial myocytes. Based on our previous metagenomic data, the relative abundance of porA, a critical bacterial enzyme for PAGln synthesis, exhibited an increased tendency in AF. In an independent cohort consisting of 42 controls without AF and 92 AF patients, plasma PAGln levels were higher in AF patients than in controls (p < 0.001) by immunoassay. Notably, PAGln exerted a predictive potential of AF with an AUC of 0.774 (p < 0.001), and a predictive model constructed based on the PAGln and Taiwan AF score further improved the predictive potential. Furthermore, a positive correlation was determined between PAGln and LA diameter. Subsequently, the effect of PAGln intervention was examined on HL-1 cells in vitro, revealing that PAGln increased apoptosis, reactive oxygen species (ROS) production, CaMKII and RyR2 activation and decreased cell viability. In conclusion, increased PAGln was associated with AF, and PAGln might contribute to the AF pathogenesis by promoting oxidative stress and apoptosis in atrial myocytes.

Cardiovasc Diabetol. 2017 Sep 29;16(1):120. (PMID: 28962617)
mSphere. 2020 Mar 18;5(2):. (PMID: 32188747)
Biomed Pharmacother. 2018 Jan;97:594-599. (PMID: 29101802)
Circ Res. 2020 Jul 31;127(4):553-570. (PMID: 32762536)
Front Cardiovasc Med. 2022 Mar 25;9:832092. (PMID: 35402559)
Circ Arrhythm Electrophysiol. 2015 Apr;8(2):409-19. (PMID: 25673629)
Gastroenterol Res Pract. 2018 Jun 3;2018:6458094. (PMID: 29967639)
Circ Res. 2008 Jun 6;102(11):1389-97. (PMID: 18467626)
Gigascience. 2019 Jun 1;8(6):. (PMID: 31149718)
J Cell Mol Med. 2020 Nov;24(22):13356-13369. (PMID: 33058365)
Mol Med Rep. 2019 Dec;20(6):5183-5189. (PMID: 31661145)
Biomedicines. 2022 Jul 21;10(7):. (PMID: 35885069)
mSystems. 2019 Dec 10;4(6):. (PMID: 31822598)
Curr Pharm Des. 2018;24(26):3062-3071. (PMID: 30179130)
Cardiovasc Res. 2016 Apr 1;109(4):542-57. (PMID: 26762270)
Eur Heart J. 2013 Jan;34(2):147-57. (PMID: 21785105)
Front Cardiovasc Med. 2021 Dec 23;8:798765. (PMID: 35004911)
Acta Physiol (Oxf). 2022 Apr;234(4):e13736. (PMID: 34709723)
J Am Heart Assoc. 2021 Sep 7;10(17):e020194. (PMID: 34459227)
Cardiovasc Eng Technol. 2021 Jun;12(3):361-372. (PMID: 33650086)
Int J Cardiol. 2013 Oct 15;168(6):5135-42. (PMID: 23993726)
Prog Cardiovasc Dis. 2021 May-Jun;66:2-9. (PMID: 34023354)
Circ Arrhythm Electrophysiol. 2008 Apr;1(1):62-73. (PMID: 19808395)
Circ Res. 2000 Oct 13;87(8):705-9. (PMID: 11029407)
J Am Coll Cardiol. 2004 Feb 4;43(3):483-90. (PMID: 15013134)
JACC Cardiovasc Imaging. 2017 Jan;10(1):65-77. (PMID: 28057220)
Trends Cardiovasc Med. 2010 Jan;20(1):30-4. (PMID: 20685575)
Trends Cardiovasc Med. 2015 Aug;25(6):475-84. (PMID: 25661032)
Cell. 2020 Mar 5;180(5):862-877.e22. (PMID: 32142679)
Circ Res. 2017 Mar 31;120(7):1183-1196. (PMID: 28360349)
Bioengineered. 2021 Dec;12(1):9021-9030. (PMID: 34657556)
Eur Heart J. 2021 Feb 1;42(5):373-498. (PMID: 32860505)
J Am Coll Cardiol. 1999 Nov 1;34(5):1577-86. (PMID: 10551709)
Pharmacol Ther. 2000 Oct;88(1):1-14. (PMID: 11033381)
Microbiome. 2020 Mar 14;8(1):36. (PMID: 32169105)
Can J Infect Dis Med Microbiol. 2021 Jan 8;2021:6658674. (PMID: 33505541)
Protein Cell. 2018 May;9(5):416-431. (PMID: 29725935)
Pacing Clin Electrophysiol. 2006 Mar;29(3):290-5. (PMID: 16606397)
Cardiovasc Res. 2022 Aug 24;118(11):2415-2427. (PMID: 34550344)
Bull Exp Biol Med. 2016 Dec;162(2):177-179. (PMID: 27909967)
Heart Rhythm. 2013 Mar;10(3):436-41. (PMID: 23178688)
Nat Rev Cardiol. 2020 Nov;17(11):732-747. (PMID: 32555383)
Nat Rev Cardiol. 2015 Apr;12(4):230-43. (PMID: 25622848)

Keywords: ROS; apoptosis; atrial fibrillation; atrial myocytes; phenylacetylglutamine

0 (Ryanodine Receptor Calcium Release Channel)
EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinase Type 2)

Date Created: 20220826 Date Completed: 20220829 Latest Revision: 20230308

20230309

PMC9405855

10.3390/biom12081120

36009014